莫雷洛替尼：首次获批。
Momelotinib: First Approval.
机构信息
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
出版信息
Drugs. 2023 Dec;83(18):1709-1715. doi: 10.1007/s40265-023-01964-8.
Momelotinib (OJJAARA) is an oral Janus kinase 1 and 2 (JAK1/JAK2) and activin A receptor, type I (ACVR1) inhibitor that has been developed for the treatment of myelofibrosis (MF). In September 2023, momelotinib was approved in the USA for the treatment of intermediate or high-risk MF, including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. This article summarizes the milestones in the development of momelotinib leading to this first approval for MF.
莫米松（OJJAARA）是一种口服 Janus 激酶 1 和 2（JAK1/JAK2）和激活素 A 受体，I 型（ACVR1）抑制剂，已被开发用于治疗骨髓纤维化（MF）。2023 年 9 月，莫米松在 美国获得批准，用于治疗中高危 MF，包括原发性 MF 或继发性 MF[真性红细胞增多症（PV）后和原发性血小板增多症（ET）后]，用于伴有贫血的成人。本文总结了莫米松开发过程中的重要里程碑，这些里程碑促成了其在 MF 方面的首次批准。
Zotero 插件